Trial ISRCTN73765130 ; EudraCT 2021-002175-19
Publication Munro APS, Lancet Infect Dis, 2022
Primary outcome on the report: 1. Anti-spike protein IgG antibody titres at 14 days; 2. cellular immune responses; 3. solicited local and systemic adverse events within 7 days of the fourth dose, unsolicited adverse events within 28 days of the fourth dose, medically attended adverse events up to 3 months following the fourth dose, adverse events of special interest, and serious adverse events. Serious adverse events and adverse events of special interest throughout the study.

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.